Veracyte, Inc. $VCYT Stock Bought by GW&K Investment Management LLC

Veracyte logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • GW&K Investment Management increased its Veracyte stake by 70.1% in the third quarter, adding 992,760 shares to own 2.41 million shares, or 3% of the company, valued at about $110.9 million.
  • Veracyte reported quarterly earnings of $0.51 per share, beating the $0.41 consensus estimate, while revenue of $151.75 million exceeded forecasts and rose 15.1% year over year.
  • Analyst sentiment was mixed, with a consensus Hold rating and a $44.50 average price target; several firms cut their targets. The article also reported that insiders sold 62,609 shares over the prior 90 days.
  • Interested in Veracyte? Here are five stocks we like better.

GW&K Investment Management LLC boosted its position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 70.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,409,303 shares of the biotechnology company's stock after purchasing an additional 992,760 shares during the quarter. Veracyte comprises about 0.9% of GW&K Investment Management LLC's portfolio, making the stock its 9th biggest position. GW&K Investment Management LLC owned 3.00% of Veracyte worth $110,924,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Focus Advisor Solutions LLC increased its position in shares of Veracyte by 22.5% during the third quarter. Focus Advisor Solutions LLC now owns 4,929 shares of the biotechnology company's stock worth $227,000 after purchasing an additional 906 shares in the last quarter. Boston Partners purchased a new stake in Veracyte in the third quarter valued at about $30,357,000. Public Sector Pension Investment Board raised its stake in Veracyte by 43.5% in the third quarter. Public Sector Pension Investment Board now owns 501,437 shares of the biotechnology company's stock valued at $21,802,000 after buying an additional 152,012 shares during the last quarter. Cibc World Market Inc. boosted its holdings in Veracyte by 6.0% in the third quarter. Cibc World Market Inc. now owns 53,521 shares of the biotechnology company's stock worth $2,464,000 after acquiring an additional 3,037 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky boosted its holdings in Veracyte by 1.3% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 52,765 shares of the biotechnology company's stock worth $2,429,000 after acquiring an additional 695 shares in the last quarter.

Veracyte Stock Down 2.1%

Shares of VCYT opened at $25.04 on Friday. Veracyte, Inc. has a 52-week low of $21.91 and a 52-week high of $60.91. The stock has a fifty day simple moving average of $40.72 and a two-hundred day simple moving average of $42.16. The company has a market capitalization of $2.02 billion, a PE ratio of 16.82 and a beta of 1.98.

Veracyte (NASDAQ:VCYT - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.51 earnings per share for the quarter, beating analysts' consensus estimates of $0.41 by $0.10. The business had revenue of $151.75 million during the quarter, compared to analysts' expectations of $147.13 million. Veracyte had a net margin of 21.80% and a return on equity of 8.99%. The business's revenue for the quarter was up 15.1% on a year-over-year basis. During the same period last year, the business earned $0.51 earnings per share. As a group, equities analysts anticipate that Veracyte, Inc. will post 1.34 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Jens Holstein sold 7,500 shares of the stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $50.00, for a total value of $375,000.00. Following the completion of the sale, the director directly owned 27,471 shares of the company's stock, valued at approximately $1,373,550. This represents a 21.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Karin Eastham sold 14,850 shares of the firm's stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $50.00, for a total transaction of $742,500.00. Following the transaction, the director directly owned 10,247 shares in the company, valued at $512,350. The trade was a 59.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 62,609 shares of company stock valued at $2,858,904 over the last ninety days. 1.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on VCYT shares. Piper Sandler dropped their price target on Veracyte from $54.00 to $30.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 10th. Wall Street Zen downgraded Veracyte from a "buy" rating to a "hold" rating in a report on Saturday, November 7th. Zacks Research downgraded Veracyte from a "strong-buy" rating to a "hold" rating in a report on Friday, October 2nd. UBS Group dropped their target price on Veracyte from $65.00 to $35.00 and set a "buy" rating on the stock in a research report on Monday, November 9th. Finally, Leerink Partners downgraded shares of Veracyte from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $55.00 to $35.00 in a report on Thursday, November 5th. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $44.50.

Read Our Latest Research Report on VCYT

About Veracyte

(Free Report)

Veracyte, Inc. is a genomic diagnostics company that develops tests to help clinicians diagnose disease and guide treatment decisions, with a focus on cancer and other complex conditions. Its tests analyze biological samples to provide information that can help distinguish between conditions and assess disease risk. The company's portfolio includes Afirma for thyroid nodule assessment, Decipher for prostate cancer, Prosigna for breast cancer, and Percepta for lung cancer. Veracyte also offers Envisia, a genomic test that supports the diagnosis of idiopathic pulmonary fibrosis and other forms of interstitial lung disease.

Featured Stories

Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Veracyte Right Now?

Before you consider Veracyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veracyte wasn't on the list.

While Veracyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines